BACKGROUND: We studied Dicer and Drosha, components of the RNA-interference machinery, in ovarian cancer. METHODS: We measured messenger RNA (mRNA) levels of Dicer and Drosha in specimens of invasive epithelial ovarian cancer from 111 patients, using a quantitative reverse-transcriptase-polymerase-chain-reaction assay, and compared the results with clinical outcomes. Validation was performed with the use of published microarray data from cohorts of patients with ovarian, breast, and lung cancer. Mutational analyses of genomic DNA from the Dicer and Drosha genes were performed in a subgroup of ovarian-cancer specimens. Dicer-dependent functional assays were performed by means of in vitro transfection with small interfering RNA (siRNA) and short hairpin RNA (shRNA). RESULTS: Levels of Dicer and Drosha mRNA correlated with the levels of expression of the corresponding protein and were decreased in 60% and 51% of ovarian-cancer specimens, respectively. Low Dicer expression was significantly associated with advanced tumor stage (P=0.007), and low Drosha expression with suboptimal surgical cytoreduction (P=0.02). Cancer specimens with both high Dicer expression and high Drosha expression were associated with increased median survival (>11 years, vs. 2.66 years for other subgroups; P<0.001). We found three independent predictors of reduced disease-specific survival in multivariate analyses: low Dicer expression (hazard ratio, 2.10; P=0.02), high-grade histologic features (hazard ratio, 2.46; P=0.03), and poor response to chemotherapy (hazard ratio, 3.95; P<0.001). Poor clinical outcomes among patients with low Dicer expression were validated in additional cohorts of patients. Rare missense mutations were found in the Dicer and Drosha genes, but their presence or absence did not correlate with the level of expression. Functional assays indicated that gene silencing with shRNA, but not siRNA, may be impaired in cells with low Dicer expression. CONCLUSIONS: Our findings indicate that levels of Dicer and Drosha mRNA in ovarian-cancer cells have associations with outcomes in patients with ovarian cancer. 2008 Massachusetts Medical Society
BACKGROUND: We studied Dicer and Drosha, components of the RNA-interference machinery, in ovarian cancer. METHODS: We measured messenger RNA (mRNA) levels of Dicer and Drosha in specimens of invasive epithelial ovarian cancer from 111 patients, using a quantitative reverse-transcriptase-polymerase-chain-reaction assay, and compared the results with clinical outcomes. Validation was performed with the use of published microarray data from cohorts of patients with ovarian, breast, and lung cancer. Mutational analyses of genomic DNA from the Dicer and Drosha genes were performed in a subgroup of ovarian-cancer specimens. Dicer-dependent functional assays were performed by means of in vitro transfection with small interfering RNA (siRNA) and short hairpin RNA (shRNA). RESULTS: Levels of Dicer and Drosha mRNA correlated with the levels of expression of the corresponding protein and were decreased in 60% and 51% of ovarian-cancer specimens, respectively. Low Dicer expression was significantly associated with advanced tumor stage (P=0.007), and low Drosha expression with suboptimal surgical cytoreduction (P=0.02). Cancer specimens with both high Dicer expression and high Drosha expression were associated with increased median survival (>11 years, vs. 2.66 years for other subgroups; P<0.001). We found three independent predictors of reduced disease-specific survival in multivariate analyses: low Dicer expression (hazard ratio, 2.10; P=0.02), high-grade histologic features (hazard ratio, 2.46; P=0.03), and poor response to chemotherapy (hazard ratio, 3.95; P<0.001). Poor clinical outcomes among patients with low Dicer expression were validated in additional cohorts of patients. Rare missense mutations were found in the Dicer and Drosha genes, but their presence or absence did not correlate with the level of expression. Functional assays indicated that gene silencing with shRNA, but not siRNA, may be impaired in cells with low Dicer expression. CONCLUSIONS: Our findings indicate that levels of Dicer and Drosha mRNA in ovarian-cancer cells have associations with outcomes in patients with ovarian cancer. 2008 Massachusetts Medical Society
Authors: Jyotsnabaran Halder; Aparna A Kamat; Charles N Landen; Liz Y Han; Susan K Lutgendorf; Yvonne G Lin; William M Merritt; Nicholas B Jennings; Arturo Chavez-Reyes; Robert L Coleman; David M Gershenson; Rosemarie Schmandt; Steven W Cole; Gabriel Lopez-Berestein; Anil K Sood Journal: Clin Cancer Res Date: 2006-08-15 Impact factor: 12.531
Authors: Simion Chiosea; Elena Jelezcova; Uma Chandran; Jianhua Luo; Geeta Mantha; Robert W Sobol; Sanja Dacic Journal: Cancer Res Date: 2007-03-01 Impact factor: 12.701
Authors: Koei Chin; Sandy DeVries; Jane Fridlyand; Paul T Spellman; Ritu Roydasgupta; Wen-Lin Kuo; Anna Lapuk; Richard M Neve; Zuwei Qian; Tom Ryder; Fanqing Chen; Heidi Feiler; Taku Tokuyasu; Chris Kingsley; Shanaz Dairkee; Zhenhang Meng; Karen Chew; Daniel Pinkel; Ajay Jain; Britt Marie Ljung; Laura Esserman; Donna G Albertson; Frederic M Waldman; Joe W Gray Journal: Cancer Cell Date: 2006-12 Impact factor: 31.743
Authors: Anna V Ivshina; Joshy George; Oleg Senko; Benjamin Mow; Thomas C Putti; Johanna Smeds; Thomas Lindahl; Yudi Pawitan; Per Hall; Hans Nordgren; John E L Wong; Edison T Liu; Jonas Bergh; Vladimir A Kuznetsov; Lance D Miller Journal: Cancer Res Date: 2006-11-01 Impact factor: 12.701
Authors: Bradley S Cobb; Arnulf Hertweck; James Smith; Eric O'Connor; Daniel Graf; Terence Cook; Stephen T Smale; Shimon Sakaguchi; Frederick J Livesey; Amanda G Fisher; Matthias Merkenschlager Journal: J Exp Med Date: 2006-10-23 Impact factor: 14.307
Authors: Andrew D Cutting; Stephanie C Bannister; Tim J Doran; Andrew H Sinclair; Mark V L Tizard; Craig A Smith Journal: Chromosome Res Date: 2012-01 Impact factor: 5.239
Authors: Hee Dong Han; Lingegowda S Mangala; Jeong Won Lee; Mian M K Shahzad; Hye Sun Kim; Deyu Shen; Eun Ji Nam; Edna M Mora; Rebecca L Stone; Chunhua Lu; Sun Joo Lee; Ju Won Roh; Alpa M Nick; Gabriel Lopez-Berestein; Anil K Sood Journal: Clin Cancer Res Date: 2010-06-10 Impact factor: 12.531
Authors: Pablo E Vivas-Mejia; Cristian Rodriguez-Aguayo; Hee-Dong Han; Mian M K Shahzad; Fatma Valiyeva; Mineko Shibayama; Arturo Chavez-Reyes; Anil K Sood; Gabriel Lopez-Berestein Journal: Clin Cancer Res Date: 2011-04-21 Impact factor: 12.531
Authors: Donald J Foster; Scott Barros; Rick Duncan; Sarfraz Shaikh; William Cantley; Amy Dell; Elena Bulgakova; Jonathan O'Shea; Nate Taneja; Satya Kuchimanchi; Christopher B Sherrill; Akin Akinc; Gregory Hinkle; Amy C Seila White; Bo Pang; Klaus Charisse; Rachel Meyers; Muthiah Manoharan; Sayda M Elbashir Journal: RNA Date: 2012-01-31 Impact factor: 4.942
Authors: William M Merritt; Alpa M Nick; Amy R Carroll; Chunhua Lu; Koji Matsuo; Melissa Dumble; Nicholas Jennings; Shuyun Zhang; Yvonne G Lin; Whitney A Spannuth; Aparna A Kamat; Rebecca L Stone; Mian M K Shahzad; Robert L Coleman; Rakesh Kumar; Anil K Sood Journal: Mol Cancer Ther Date: 2010-04-06 Impact factor: 6.261
Authors: Andrew Jakymiw; Rushi S Patel; Natasha Deming; Indraneel Bhattacharyya; Priya Shah; Richard J Lamont; Carol M Stewart; Donald M Cohen; Edward K L Chan Journal: Genes Chromosomes Cancer Date: 2010-06 Impact factor: 5.006